Researchers at the University of Cape Town are developing a low-cost vaccine manufacturing platform using Pichia pastoris, a species of yeast commonly found in compost, to address vaccine inequity in Africa. By utilizing this fungal protein expression system, scientists aim to produce essential vaccines at a cost of approximately one dollar per dose, significantly reducing reliance on imported medical supplies.
Why is yeast being used for vaccine production?
The shift toward using Pichia pastoris—a methylotrophic yeast—stems from its ability to act as a "biological factory." According to the University of Cape Town, the yeast can be genetically engineered to produce specific proteins that trigger an immune response in humans.
Unlike traditional methods that often require complex mammalian cell cultures and expensive bioreactors, yeast-based production is robust and scalable. The process involves inserting the genetic code for a pathogen’s surface protein into the yeast, which then expresses the protein as it grows. This method has been used for decades to produce insulin and hepatitis B vaccines, but researchers are now adapting it to create more affordable versions of complex vaccines for regional distribution.
How does this address vaccine inequity?
Vaccine manufacturing in Africa has historically been limited, with the continent importing over 99% of its routine vaccines, according to the Africa Centres for Disease Control and Prevention (Africa CDC). This dependency creates supply chain vulnerabilities, as seen during the COVID-19 pandemic when global distribution was heavily skewed toward wealthier nations.
By establishing local manufacturing hubs, African nations can bypass international logistics bottlenecks. The goal of the project is to lower production costs to roughly $1 per dose. This price point is intended to make life-saving immunizations sustainable for national health budgets and Gavi-supported programs, ensuring that supply is not dictated by global market fluctuations.
What are the current challenges in implementation?
While the technology shows promise, moving from a laboratory setting to industrial-scale manufacturing requires rigorous validation. The World Health Organization (WHO) mandates strict Good Manufacturing Practice (GMP) standards for all vaccines.
Transitioning the yeast-based platform to a certified facility involves:
- Regulatory Approval: Ensuring that the protein expression remains consistent across large batches.
- Infrastructure: Developing the specialized cold-chain and facility requirements necessary for large-scale pharmaceutical output.
- Technology Transfer: Training local workforces to manage the high-tech fermentation processes required to maintain the yeast cultures.
Comparison of vaccine production platforms
| Feature | Mammalian Cell Culture | Pichia pastoris (Yeast) |
|---|---|---|
| Cost | High (expensive media) | Low (simple nutrients) |
| Growth Speed | Slow | Rapid |
| Complexity | High infrastructure needs | Lower infrastructure needs |
| Scalability | Challenging | Highly scalable |
What happens next?
The project is part of a broader push to increase vaccine sovereignty on the continent. The African Union has set a target to produce 60% of the vaccines used on the continent by 2040. As the University of Cape Town continues its research, the focus will move toward clinical trials and partnerships with regional manufacturers to prove that the yeast-derived antigens are as safe and effective as those currently available on the global market. Success in this endeavor would mark a shift in how low- and middle-income countries manage public health crises, moving from reactive procurement to proactive, domestic production.
Keep reading